Literature DB >> 31798836

Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension.

David G Kiely1,2,3, Orla Doyle4, Edmund Drage4, Harvey Jenner4, Valentina Salvatelli4, Flora A Daniels4, John Rigg4, Claude Schmitt5, Yevgeniy Samyshkin5, Allan Lawrie2,3, Rito Bergemann6.   

Abstract

Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often diagnosed at an advanced stage. Despite increased awareness, the delay to diagnosis remains unchanged. This study explores whether a predictive model based on healthcare resource utilisation can be used to screen large populations to identify patients at high risk of idiopathic pulmonary arterial hypertension. Hospital Episode Statistics from the National Health Service in England, providing close to full national coverage, were used as a measure of healthcare resource utilisation. Data for patients with idiopathic pulmonary arterial hypertension from the National Pulmonary Hypertension Service in Sheffield were linked to pre-diagnosis Hospital Episode Statistics records. A non-idiopathic pulmonary arterial hypertension control cohort was selected from the Hospital Episode Statistics population. Patient history was limited to ≤5 years pre-diagnosis. Information on demographics, timing/frequency of diagnoses, medical specialities visited and procedures undertaken was captured. For modelling, a bagged gradient boosting trees algorithm was used to discriminate between cohorts. Between 2008 and 2016, 709 patients with idiopathic pulmonary arterial hypertension were identified and compared with a stratified cohort of 2,812,458 patients classified as non-idiopathic pulmonary arterial hypertension with ≥1 ICD-10 coded diagnosis of relevance to idiopathic pulmonary arterial hypertension. A predictive model was developed and validated using cross-validation. The timing and frequency of the clinical speciality seen, secondary diagnoses and age were key variables driving the algorithm's performance. To identify the 100 patients at highest risk of idiopathic pulmonary arterial hypertension, 969 patients would need to be screened with a specificity of 99.99% and sensitivity of 14.10% based on a prevalence of 5.5/million. The positive predictive and negative predictive values were 10.32% and 99.99%, respectively. This study highlights the potential application of artificial intelligence to readily available real-world data to screen for rare diseases such as idiopathic pulmonary arterial hypertension. This algorithm could provide low-cost screening at a population level, facilitating earlier diagnosis, improved diagnostic rates and patient outcomes. Studies to further validate this approach are warranted.
© The Author(s) 2019.

Entities:  

Keywords:  diagnosis; idiopathic pulmonary arterial hypertension (PAH); machine learning; predictive algorithm

Year:  2019        PMID: 31798836      PMCID: PMC6868581          DOI: 10.1177/2045894019890549

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  23 in total

Review 1.  Pulmonary arterial hypertension: epidemiology and registries.

Authors:  Michael D McGoon; Raymond L Benza; Pilar Escribano-Subias; Xin Jiang; Dave P Miller; Andrew J Peacock; Joanna Pepke-Zaba; Tomas Pulido; Stuart Rich; Stephan Rosenkranz; Samy Suissa; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

2.  Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies.

Authors:  Jérôme Avouac; Paolo Airò; Christophe Meune; Lorenzo Beretta; Philippe Dieude; Paola Caramaschi; Kiet Tiev; Susanna Cappelli; Elisabeth Diot; Alessandra Vacca; Jean-Luc Cracowski; Jean Sibilia; André Kahan; Marco Matucci-Cerinic; Yannick Allanore
Journal:  J Rheumatol       Date:  2010-09-01       Impact factor: 4.666

Review 3.  Early detection of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Marc Humbert; David S Celermajer
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

4.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.

Authors:  W E Hopkins; L L Ochoa; G W Richardson; E P Trulock
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

5.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

6.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

7.  Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class.

Authors:  Robert Dufour; Janis Pruett; Nan Hu; Cassandra Lickert; Stephen Stemkowski; Yuen Tsang; Daniel Lane; William Drake
Journal:  J Med Econ       Date:  2017-08-11       Impact factor: 2.448

8.  Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.

Authors:  Geoff Strange; David Playford; Simon Stewart; Jenny A Deague; Helen Nelson; Aaron Kent; Eli Gabbay
Journal:  Heart       Date:  2012-07-03       Impact factor: 5.994

9.  Transforming health policy through machine learning.

Authors:  Hutan Ashrafian; Ara Darzi
Journal:  PLoS Med       Date:  2018-11-13       Impact factor: 11.069

10.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

View more
  5 in total

Review 1.  Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.

Authors:  Christopher J Rhodes; Andrew J Sweatt; Bradley A Maron
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

2.  Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.

Authors:  Yasmina Bauer; Simon de Bernard; Peter Hickey; Karri Ballard; Jeremy Cruz; Peter Cornelisse; Harbajan Chadha-Boreham; Oliver Distler; Daniel Rosenberg; Martin Doelberg; Sebastien Roux; Oliver Nayler; Allan Lawrie
Journal:  Eur Respir J       Date:  2021-06-24       Impact factor: 16.671

3.  Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda.

Authors:  Yogesh Kumar; Apeksha Koul; Ruchi Singla; Muhammad Fazal Ijaz
Journal:  J Ambient Intell Humaniz Comput       Date:  2022-01-13

4.  Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.

Authors:  Allan Lawrie; Neil Hamilton; Steven Wood; Fernando Exposto; Ruvimbo Muzwidzwa; Louise Raiteri; Amélie Beaudet; Audrey Muller; Rafael Sauter; Nadia Pillai; David G Kiely
Journal:  Pulm Circ       Date:  2022-09-30       Impact factor: 2.886

Review 5.  Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension.

Authors:  Shahood Fazal; Malik Bisserier; Lahouaria Hadri
Journal:  Cells       Date:  2021-03-13       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.